Navigation Links
Particle Sciences and Pernix Therapeutics Enter into an Agreement to Develop a Pediatric Dermatology Product
Date:3/21/2012

BETHLEHEM, Pa., March 21, 2012 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, today announced that it is developing with Pernix Therapeutics, a specialty pharmaceutical company, a new topical dermatology product for the pediatric market.

Mark Mitchnick, CEO of Particle Sciences, said, "There are multiple treatments for many pediatric skin conditions.  The unmet need is in the delivery of these agents via a more convenient, and improved vehicle.  Particle Sciences is applying advanced drug delivery and formulation technologies to an established pediatric product category.  For parents, this product is designed to be a potentially better and easier to use product."

Cooper Collins, Pernix Therapeutics' President and CEO, said, "We are enthusiastic about working with Particle Sciences for this product candidate, which may be another opportunity to further expand our pediatric product line."

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.comor contact us at (610) 861-4701 for information.

Contact:  Maureen Mattera, (610) 861-4701, mmattera@particlesciences.com


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Particle Sciences Hires Robert Gwozdz to Head Oral Formulation
4. Brabender® Pharma USA, Inc. and Particle Sciences Cooperate to Expand Extrusion Capabilities
5. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
6. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
7. Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services
8. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
9. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
10. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
11. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... YORK , Jan. 17, 2016  Attorney Advertising -- ... behalf of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the ... to obtain additional information and assist the investigation by visiting ... concerns whether Anthera and certain of its officers and/or directors ... Act of 1934. ...
(Date:1/17/2017)... , Jan. 17, 2017  In a letter ... Jo Ann Jenkins outlines AARP,s priorities for ... Social Security, ensuring access to affordable health care coverage, ... In the letter Jenkins writes to President-elect Trump that ... Americans are counting on you to protect their Medicare ...
(Date:1/17/2017)... , Jan. 17, 2017 Immune Pharmaceuticals (NASDAQ: ... company, announced today that it will hold a Satellite Symposium ... Acute Leukemias (ISAL) XVI in Munich, Germany ... "Reinforcing the Efficacy of Immunotherapy for the maintenance of ... on Monday February 20 th , 2017 from 12:45 – ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... NJ (PRWEB) , ... January 17, 2017 , ... Neil ... and financial planning assistance to communities throughout the region, is launching a charity drive ... Heart disease is by far the deadliest killer in America, and is responsible for ...
(Date:1/17/2017)... ... 2017 , ... Livionex, Inc., a Silicon Valley healthcare company focused on treating ... its dental gel that shows significant reduction in plaque levels and gum inflammation and ... was conducted at the Beckman Laser Institute at UC Irvine and has been published ...
(Date:1/17/2017)... ... 17, 2017 , ... The Sharie Withers Agency, a full-service ... latest beneficiary of their thriving community involvement program. The current campaign fundraises to ... dreams of terminally ill patients. Donations to this worthy cause may now be ...
(Date:1/17/2017)... ... 17, 2017 , ... Today, FloSports , a global leader in live ... as part of a long-term extension of their media partnership. The partnership, which began ... of the sport’s premier events exclusively on FloWrestling.com as well as usage of the ...
Breaking Medicine News(10 mins):